Sera Prognostics Inc (SERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sera Prognostics Inc (SERA) has a cash flow conversion efficiency ratio of -0.079x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.48 Million) by net assets ($82.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sera Prognostics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sera Prognostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SERA total liabilities for a breakdown of total debt and financial obligations.
Sera Prognostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sera Prognostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fluoguide AS
ST:FLUO
|
4.485x |
|
Sentelic Corp
TWO:4945
|
-0.084x |
|
Tainet Communication System
TWO:4905
|
0.016x |
|
Cosmax Nbt Inc
KQ:222040
|
0.073x |
|
COWELL FASHION Co.Ltd
KQ:033290
|
0.022x |
|
ELUON Corporation
KQ:065440
|
-0.017x |
|
KENERGY
KLSE:0307
|
0.020x |
|
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
|
0.018x |
Annual Cash Flow Conversion Efficiency for Sera Prognostics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sera Prognostics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SERA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.80 Million | $-14.19 Million | -0.297x | +23.41% |
| 2023-12-31 | $70.16 Million | $-27.19 Million | -0.388x | -10.79% |
| 2022-12-31 | $98.94 Million | $-34.61 Million | -0.350x | -53.21% |
| 2021-12-31 | $138.56 Million | $-31.64 Million | -0.228x | +96.02% |
| 2020-12-31 | $2.94 Million | $-16.87 Million | -5.737x | -225.29% |
| 2019-12-31 | $10.96 Million | $-19.32 Million | -1.764x | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel bl… Read more